Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma

被引：26

作者：

DeLeon, Thomas T. ^{[1
]}

Ahn, Daniel H. ^{[1
]}

Bogenberger, James M. ^{[1
]}

Anastasiadis, Panos Z. ^{[2
]}

Arora, Mansi ^{[1
]}

Ramanathan, Ramesh K. ^{[1
]}

Aqel, Bashar A. ^{[3
]}

Vasmatzis, George ^{[4
]}

Truty, Mark J. ^{[5
]}

Oklu, Rahmi ^{[6
]}

Bekaii-Saab, Tanios S. ^{[1
]}

Borad, Mitesh J. ^{[1
]}

机构：

[1] Mayo Clin, Dept Med, Div Hematol Oncol, Scottsdale, AZ 85259 USA

[2] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA

[3] Mayo Clin, Dept Med, Div Gastroenterol & Hepatol, Scottsdale, AZ 85259 USA

[4] Mayo Clin, Dept Lab Med & Pathol, Dept Mol Med, Rochester, MN 55902 USA

[5] Mayo Clin, Dept Surg, Div Hepatobiliary & Pancreat Surg, Rochester, MN 55902 USA

[6] Mayo Clin, Dept Radiol, Div Intervent Radiol, Scottsdale, AZ 85259 USA

来源：

FUTURE ONCOLOGY | 2018年 / 14卷 / 06期

关键词：

biomarkers; cholangiocarcinoma; gallbladder cancer; hepatocellular cancer; immunotherapy; targeted therapy; GROWTH-FACTOR-RECEPTOR; TELOMERE TERMINAL TRANSFERASE; C-MET EXPRESSION; INTRAHEPATIC CHOLANGIOCARCINOMA; MUTATIONAL LANDSCAPE; PROGNOSTIC-SIGNIFICANCE; NEGATIVE REGULATOR; CLINICAL-RESPONSE; TUMOR-SUPPRESSOR; RISING INCIDENCE;

D O I：

10.2217/fon-2017-0451

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Worldwide hepatobiliary cancers are the second leading cause of cancer related death. Despite their relevance, hepatobiliary cancers have a paucity of approved systemic therapy options. However, there are a number of emerging therapeutic biomarkers and therapeutic concepts that show promise. In hepatocellular carcinoma, nivolumab appears particularly promising and recently received US FDA approval. In intrahepatic cholangiocarcinoma, therapies targeting FGFR2 and IDH1 and immune checkpoint inhibitors are the furthest along and generating the most excitement. There are additional biomarkers that merit further exploration in hepatobiliary cancers including FGF19, ERRFI1, TERT, BAP1, BRAF, CDKN2A, tumor mutational burden and ERBB2 (HER2/neu). Development of new and innovative therapies would help address the unmet need for effective systemic therapies in advanced and metastatic hepatobiliary cancers.

引用

页码：553 / 566

页数：14

共 117 条

[41] Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis [J].

Inagaki, T ;

Choi, M ;

Moschetta, A ;

Peng, L ;

Cummins, CL ;

McDonald, JG ;

Luo, G ;

Jones, SA ;

Goodwin, B ;

Richardson, JA ;

Gerard, RD ;

Repa, JJ ;

Mangelsdorf, DJ ;

Kliewer, SA .

CELL METABOLISM, 2005, 2 (04) :217-225

[42]

Iwadate Y, 2000, INT J ONCOL, V17, P501

[43] Biliary Cancer: Utility of Next-Generation Sequencing for Clinical Management [J].

Javle, Milind ;

Bekaii-Saab, Tanios ;

Jain, Apurva ;

Wang, Ying ;

Kelley, Robin Katie ;

Wang, Kai ;

Kang, Hyunseon C. ;

Catenacci, Daniel ;

Ali, Siraj ;

Krishnan, Sunil ;

Ahn, Daniel ;

Bocobo, Andrea Grace ;

Zuo, Mingxin ;

Kaseb, Ahmed ;

Miller, Vincent ;

Stephens, Philip J. ;

Meric-Bernstam, Funda ;

Shroff, Rachna ;

Ross, Jeffrey .

CANCER, 2016, 122 (24) :3838-3847

[44] HER2/neu-directed therapy for biliary tract cancer [J].

Javle, Milind ;

Churi, Chaitanya ;

Kang, HyunSeon C. ;

Shroff, Rachna ;

Janku, Filip ;

Surapaneni, Rakesh ;

Zuo, Mingxin ;

Barrera, Christian ;

Alshamsi, Humaid ;

Krishnan, Sunil ;

Mishra, Lopa ;

Wolff, Robert A. ;

Kaseb, Ahmed O. ;

Thomas, Melanie B. ;

Siegel, Abby B. .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8

[45] A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy. [J].

Javle, Milind M. ;

Shroff, Rachna T. ;

Zhu, Andrew ;

Sadeghi, Saeed ;

Choo, Supin ;

Borad, Mitesh J. ;

Lowery, Maeve Aine ;

El-Khoueiry, Anthony ;

Macarulla, Teresa ;

Philip, Agop Philip ;

Oh, Do-Youn ;

Van Cutsem, Eric ;

Yeh, Kun-Huei ;

Isaacs, Randi ;

McGarry, Carolyn ;

Sen, Suman ;

Bekaii-Saab, Tanios S. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)

[46] A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score [J].

Jiang, W. ;

Zeng, Z. -C. ;

Tang, Z. -Y. ;

Fan, J. ;

Sun, H. -C. ;

Zhou, J. ;

Zeng, M. -S. ;

Zhang, B. -H. ;

Ji, Y. ;

Chen, Y. -X. .

ANNALS OF ONCOLOGY, 2011, 22 (07) :1644-1652

[47] Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas [J].

Jiao, Yuchen ;

Pawlik, Timothy M. ;

Anders, Robert A. ;

Selaru, Florin M. ;

Streppel, Mirte M. ;

Lucas, Donald J. ;

Niknafs, Noushin ;

Guthrie, Violeta Beleva ;

Maitra, Anirban ;

Argani, Pedram ;

Offerhaus, G. Johan A. ;

Roa, Juan Carlos ;

Roberts, Lewis R. ;

Gores, Gregory J. ;

Popescu, Irinel ;

Alexandrescu, Sorin T. ;

Dima, Simona ;

Fassan, Matteo ;

Simbolo, Michele ;

Mafficini, Andrea ;

Capelli, Paola ;

Lawlor, Rita T. ;

Ruzzenente, Andrea ;

Guglielmi, Alfredo ;

Tortora, Giampaolo ;

de Braud, Filippo ;

Scarpa, Aldo ;

Jarnagin, William ;

Klimstra, David ;

Karchin, Rachel ;

Velculescu, Victor E. ;

Hruban, Ralph H. ;

Vogelstein, Bert ;

Kinzler, Kenneth W. ;

Papadopoulos, Nickolas ;

Wood, Laura D. .

NATURE GENETICS, 2013, 45 (12) :1470-U93

[48] Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models Carrying Heterozygous Germline Bap1 Mutations [J].

Kadariya, Yuwaraj ;

Cheung, Mitchell ;

Xu, Jinfei ;

Pei, Jianming ;

Sementino, Eleonora ;

Menges, Craig W. ;

Cai, Kathy Q. ;

Rauscher, Frank J. ;

Klein-Szanto, Andres J. ;

Testa, Joseph R. .

CANCER RESEARCH, 2016, 76 (09) :2836-2844

[49] Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment [J].

Kaibori, Masaki ;

Sakai, Kazuko ;

Ishizaki, Morihiko ;

Matsushima, Hideyuki ;

De Velasco, Marco A. ;

Matsui, Kosuke ;

Iida, Hiroya ;

Kitade, Hiroaki ;

Kwon, A-Hon ;

Nagano, Hiroaki ;

Wada, Hiroshi ;

Haji, Seiji ;

Tsukamoto, Tadashi ;

Kanazawa, Akishige ;

Takeda, Yutaka ;

Takemura, Shigekazu ;

Kubo, Shoji ;

Nishio, Kazuto .

ONCOTARGET, 2016, 7 (31) :49091-49098

[50] Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study [J].

Kelley, R. K. ;

Verslype, C. ;

Cohn, A. L. ;

Yang, T. -S. ;

Su, W. -C. ;

Burris, H. ;

Braiteh, F. ;

Vogelzang, N. ;

Spira, A. ;

Foster, P. ;

Lee, Y. ;

Van Cutsem, E. .

ANNALS OF ONCOLOGY, 2017, 28 (03) :528-534

← 1 2 3 4 5 6 7 8 9 10 →